Business Development

Goldilocks has developed mesoscale nanoparticle (MNP) versions of small molecules, RNA/DNA, and peptides that specifically target the renal tubules – and proteins/antibodies should be amenable to this approach as well. In addition to pursuing MNP versions of both novel and already marketed drugs for its own account, Goldilocks intends to partner with companies that have proprietary drug payloads that they wish to specifically target to the renal tubules.

For more information about our technology or to discuss a potential collaboration, please contact us at